Arcline agrees Akron Bio sale to MaxCyte in $152m deal
Thursday, November 12, 2026 · first reported by PEI Private Equity
Arcline agreed to sell Akron Bio to MaxCyte in a $152m deal.
- Firm
- Arcline
- Also named
- Akron Bio, MaxCyte
- Deal value
- $152M
- Asset class
- Private equity
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
See an error?
- Apollo’s £5.7bn easyJet takeover wins shareholder approvalPrivate Equity Wire
- KKR and RWE finalise $16bn UK offshore wind investmentPrivate Equity Wire +4
- DTE Energy to sell DTE Vantage business to J.P. Morgan for $3bIREI
- Barings to acquire Irish Residential Properties REIT for €731mIREI
- Blackstone builds on Pfizer ties with $1.5bn obesity drug investmentAlternatives Watch
- Calpers doubles investment in Grain Management spectrum deal with SpaceXPrivate Equity Wire
Got news? Send it to us →